Abstracts tagged "Takayasu.s arteritis and vasculitis"

Abstract Number: 2364 • 2012 ACR/ARHP Annual Meeting
CROSS-Sectional Assessment of Damage in Takayasu Arteritis with A Validated Tool
Ahmet Omma¹, Burak Erer², Omer Karadag³, Neslihan Yilmaz⁴, Fatma Alibaz-Oner⁵, Fatih Yildiz⁶, Melike Kalfa⁷, Gezmis Kimyon⁸, Sedat Kiraz⁹, Haner Direskeneli⁵, Eren Erken¹⁰, Kenan Aksu¹¹, Ahmet Mesut Onat¹², Ahmet Gul², Lale Ocal², Murat Inanc² and Sevil Kamali¹³, ¹Internal Medicine Department, Rheumatology Division, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, ²Department of Internal Medicine, Rheumatology Division, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, ³Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey, ⁴Department of Rheumatology, Bilim University Faculty of Medicine, Istanbul, Turkey, ⁵Division of Rheumatology, Department of Internal Medicine, Marmara University, Faculty of Medicine, Istanbul, Turkey, ⁶Rheumatology, Cukurova University, School of Medicine, Adana, Turkey, ⁷Dept. of Internal Medicine, Division of Rheumatology, Ege University, Faculty of Medicine, Izmir, Turkey, ⁸Department of Rheumatology, Gaziantep University School of Medicine, Gaziantep, Turkey, ⁹Division of Rheumatology, Department of Internal Medicine, Hacettepe University, Faculty of Medicine, Ankara, Turkey, ¹⁰Rheumatology, Cukurova University School of Medicine, Adana, Turkey, ¹¹Rheumatology, Ege University School of Medicine, Izmir, Turkey, ¹²Rheumatology, Gaziantep University School of Medicine, Gaziantep, Turkey, ¹³Department of Internal Medicine, Division of Rheumatology, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey
Background/Purpose: Takayasu arteritis (TA) is a large vessel vasculitis with a chronic course, usually causing damage by the time of diagnosis. To our knowledge, there…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].